课题基金 / 基金详情

项目摘要

项目成果

ANDREW BAIRD的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): We propose an 14 month, milestone-driven, benchmarked research plan that extends a parent P20 Center grant focusing on bio-therapeutics development. The research will initially be executed by 6 newly hired academic research and technical positions at UCSD. Sustained and new employment in drug discovery, drug screening and drug development will be developed by partnerships with the San Diego's local biotechnology community. Specifically we will: (1) express a newly discovered recombinant neuropeptide protein that we identified in the parent grant (P20 GM078421). Analogs will be synthesized to identify functional domains and test agonists and antagonists. (2) develop high specificity monoclonal antibodies and create a quantitative ELISA assay to measure its role in disease. (3) evaluate preclinical models of wound repair by creating models of gene knock down and conditional knock outs to (a) establish its physiological relevance, (b) serve as models for drug discovery and (c) assist in converting the drug candidate to a drug lead. (4) identify its receptor by molecular cloning to establish an assay for drug discovery. (5) map the promoter to create a luciferase reporter transgenic mouse. (6) transfer technology generated to the private sector for further development. Funding will build on the success of the parent project, extend its scope, bring new fundamental skills to the laboratory, accelerate the tempo of scientific research and allow for significant job creation (and retention) by enabling hiring of additional staff, increasing hours of current part-time staff, and contracting for additional needed skills. The funded program will create 6 new full time positions, enable us to sustain 2 ongoing current research positions and with a successful outcome, we anticipate would generate an additional 5-15 new jobs in drug development research positions by technology transfer to the private biotechnology sector. Relevance: This research project describes 5 milestone and bench-marked specific AIMs that will create, test and validate a new therapeutic for wound healing. It will immediately create 6 full time positions and, if successful, its 6th AIM will create 5-15 new jobs by technology transfer to the private sector.
期刊论文(39)
专著(0)
科研奖励(0)
会议论文
DOI: 10.1016/j.surg.2009.05.007
发表时间: 2009-08
期刊: SURGERY
影响因子: 3.8
作者: [Costantini, Todd W., Putnam, James G., Sawada, Ritsuko, Baird, Andrew, Loomis, William H., Eliceiri, Brian P., Bansal, Vishal, Coimbra, Raul]
通讯作者: Coimbra, Raul
DOI: 10.1097/ta.0b013e318191bb1f
发表时间: 2009-01
期刊: The Journal of trauma
影响因子: --
作者: [Costantini TW, Loomis WH, Putnam JG, Kroll L, Eliceiri BP, Baird A, Bansal V, Coimbra R]
通讯作者: Coimbra R
DOI: 10.1186/2045-8118-8-6
发表时间: 2011-01-18
期刊: Fluids and barriers of the CNS
影响因子: 7.3
作者: [Gonzalez AM, Podvin S, Lin SY, Miller MC, Botfield H, Leadbeater WE, Roberton A, Dang X, Knowling SE, Cardenas-Galindo E, Donahue JE, Stopa EG, Johanson CE, Coimbra R, Eliceiri BP, Baird A]
通讯作者: Baird A
DOI: 10.1186/1743-8454-7-13
发表时间: 2010-08-13
期刊: Cerebrospinal fluid research
影响因子: --
作者: [Gonzalez AM, Taylor WM, Johanson CE, King JC, Leadbeater WE, Stopa EG, Baird A]
通讯作者: Baird A
25
    Targeting the choroid plexus for drug translocation into CSF
    Targeting the choroid plexus for drug translocation into CSF
    Targeting the choroid plexus for drug translocation into CSF
    Targeting the choroid plexus for drug translocation into CSF
    国内基金
    海外基金
    Segmented Filamentous Bacteria激活宿主免疫系统抑制其拮抗菌 Enterobacteriaceae维持菌群平衡及其机制研究
    • 批准号:
      81971557
    • 项目类别:
      面上项目
    • 资助金额:
      65.0万元
    • 批准年份:
      2019
    • 负责人:
      毛开睿
    • 依托单位:
    电缆细菌(Cable bacteria)对水体沉积物有机污染的响应与调控机制